Kathleen Reape
Corporate Officer/Principal presso AKOUOS
Profilo
Kathleen Reape currently works at Akouos, Inc., as Chief Development Officer from 2021.
Dr. Reape also formerly worked at Taysha Gene Therapies, Inc., as Independent Director from 2020 to 2023, Actavis, Inc., as Senior Vice President-Clinical Development, Allergan Ltd.
(Ireland), as Senior Vice President-Clinical Development in 2015, Spark Therapeutics, Inc., as Chief Medical Officer from 2018 to 2020, and Ark Medical Consulting LLC, as President from 2015 to 2016.
Dr. Reape received her graduate degree and doctorate degree from the University of Pennsylvania.
Posizioni attive di Kathleen Reape
Società | Posizione | Inizio |
---|---|---|
AKOUOS | Corporate Officer/Principal | 07/05/2021 |
Precedenti posizioni note di Kathleen Reape
Società | Posizione | Fine |
---|---|---|
TAYSHA GENE THERAPIES, INC. | Direttore/Membro del Consiglio | 01/11/2023 |
SPARK THERAPEUTICS, INC. | Direttore Tecnico/Scientifico/R&S | 01/03/2020 |
Ark Medical Consulting LLC | Presidente | 01/01/2016 |
ALLERGAN PLC | Direttore Tecnico/Scientifico/R&S | 01/07/2015 |
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Kathleen Reape
University of Pennsylvania | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Società quotate in Borsa | 1 |
---|---|
TAYSHA GENE THERAPIES, INC. | Health Technology |
Aziende private | 5 |
---|---|
Spark Therapeutics, Inc.
Spark Therapeutics, Inc. BiotechnologyHealth Technology Spark Therapeutics, Inc. engages in the research, development, and commercialization of gene therapies. Its product portfolio intends to treat inherited retinal sickness, liver-mediated, and neurodegenerative diseases. The company was founded by Jean Bennett, Beverly Davidson, Katherine A. High, Jeffrey D. Marrazzo, J. Fraser Wright, and Jennifer Wellman on March 13, 2013 and is headquartered in Philadelphia, PA. | Health Technology |
Ark Medical Consulting LLC | |
Allergan Ltd. (Ireland)
Allergan Ltd. (Ireland) Pharmaceuticals: MajorHealth Technology Allergan Plc engages in the research, development, and manufacture of pharmaceutical products. It operates through the following business segments: US Specialized Therapeutics; US General Medicine, and International. The US Specialized Therapeutics segment includes sales and expenses relating to branded products within the United States. The US General Medicine segment involves Central Nervous System; Gastrointestinal; Women's Health; Anti-Infectives; and Diversified brands. The International segment comprises of products sold outside the United States. The company was founded in 1982 and is headquartered in Dublin, Ireland. | Health Technology |
Akouos, Inc.
Akouos, Inc. BiotechnologyHealth Technology Akouos, Inc. is a precision genetic medicine company, which engages in the development of precision genetic medicines to restore and preserve hearing in genetically-defined patient populations. The firm's lead product candidate, AK-OTOF, is a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. It develops targeted adeno-associated viral vector based gene therapies for sensorineural hearing loss, which results from dysfunction or damage to sensory cells and nerve fibers of the inner ear. The company was founded by Emmanuel J. Simons, William F. Sewell, Richard H. Smith, Luk H. Vandenberghe, and Michael J. McKenna on March 7, 2016 and is headquartered in Boston, MA. | Health Technology |
Actavis, Inc.
Actavis, Inc. Pharmaceuticals: MajorHealth Technology Actavis, Inc. is a pharmaceutical company. It focuses on the development and distribution of generic products. The company engages in developing, manufacturing and marketing generic, branded generic, legacy brands and over-the-counter products. It operates its business in three segments: Actavis Pharma, Actavis Specialty Brands and Distribution. The Actavis Pharma segment develops and out-licenses generic pharmaceutical products outside the U.S. through its medis third-party business. The Actavis Specialty Brands segment engages in developing and marketing biosimilars products in women's health, oncology and other therapeutic categories. The Distribution segment distributes generic, select brand pharmaceutical products, vaccines, injectables and over-the-counter medicines from suppliers to independent pharmacies, alternate care providers, pharmacy chains and physicians offices. The company was founded by Allen Y. Chao and David C. Hsia in 1984 and is headquartered in Parsippany, NJ. | Health Technology |
- Borsa valori
- Insiders
- Kathleen Reape